274 related articles for article (PubMed ID: 30141279)
21. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
23. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making.
Favaloro EJ
Thromb Res; 2020 Apr; 188():17-24. PubMed ID: 32036157
[TBL] [Abstract][Full Text] [Related]
24. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
Favaloro EJ; Thom J; Patterson D; Just S; Baccala M; Dixon T; Meiring M; Koutts J; Rowell J; Baker R
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
[TBL] [Abstract][Full Text] [Related]
25. Acquired von Willebrand syndrome in patients with Gaucher disease.
Mitrovic M; Elezovic I; Miljic P; Suvajdzic N
Blood Cells Mol Dis; 2014 Apr; 52(4):205-7. PubMed ID: 24275154
[TBL] [Abstract][Full Text] [Related]
26. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
27. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome.
Casonato A; Pontara E; Doria A; Bertomoro A; Cattini MG; Gambari PF; Girolami A
Br J Haematol; 2002 Mar; 116(4):899-904. PubMed ID: 11886398
[TBL] [Abstract][Full Text] [Related]
28. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
30. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB).
Favaloro EJ; Mohammed S
Methods Mol Biol; 2017; 1646():417-433. PubMed ID: 28804845
[TBL] [Abstract][Full Text] [Related]
31. Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis.
Binnetoğlu FK; Babaoğlu K; Filiz ŞG; Zengin E; Altun G; Kılıç SÇ; Sarper N
Cardiovasc J Afr; 2016; 27(4):222-227. PubMed ID: 27841910
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Lavin M; Brophy TM; Rawley O; O'Sullivan JM; Hayden PJ; Browne PV; Ryan K; O'Connell N; O'Donnell JS
J Thromb Haemost; 2016 Jun; 14(6):1200-5. PubMed ID: 26991062
[TBL] [Abstract][Full Text] [Related]
33. Acquired von Willebrand Syndrome: An Under-Recognized Cause of Major Bleeding in the Cardiac Intensive Care Unit.
Jones MB; Ramakrishnan K; Alfares FA; Endicott KM; Oldenburg G; Berger JT; Shankar V; Nath DS; Diab YA
World J Pediatr Congenit Heart Surg; 2016 Nov; 7(6):711-716. PubMed ID: 27834763
[TBL] [Abstract][Full Text] [Related]
34. Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH).
Wieland I; Diekmann F; Carlens J; Hinze L; Lambeck K; Jack T; Hansmann G
Front Pediatr; 2022; 10():1012738. PubMed ID: 36452355
[TBL] [Abstract][Full Text] [Related]
35. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: Rapid onset and fast recovery.
Kalbhenn J; Schlagenhauf A; Rosenfelder S; Schmutz A; Zieger B
J Heart Lung Transplant; 2018 Aug; 37(8):985-991. PubMed ID: 29650295
[TBL] [Abstract][Full Text] [Related]
36. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.
Dicke C; Schneppenheim S; Holstein K; Spath B; Bokemeyer C; Dittmer R; Budde U; Langer F
Ann Hematol; 2016 May; 95(6):945-57. PubMed ID: 27040683
[TBL] [Abstract][Full Text] [Related]
37. Acquired von Willebrand syndrome--report of 10 cases and review of the literature.
Nitu-Whalley IC; Lee CA
Haemophilia; 1999 Sep; 5(5):318-26. PubMed ID: 10583513
[TBL] [Abstract][Full Text] [Related]
38. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart.
Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Benk C; Berchtold-Herz M; Trummer G; Schlensak C; Zieger B
Thromb Haemost; 2010 May; 103(5):962-7. PubMed ID: 20352153
[TBL] [Abstract][Full Text] [Related]
39. [Acquired von Willebrand syndrome with autoimmune hemolytic anemia].
Ishimaru F; Hayashi H; Fujita T; Tsurumi N; Tsuda T; Kimura I
Rinsho Ketsueki; 1990 Sep; 31(9):1493-8. PubMed ID: 2246822
[TBL] [Abstract][Full Text] [Related]
40. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
